MTOR, mechanistic target of rapamycin kinase, 2475

N. diseases: 960; N. variants: 48
Disease: B-cell lymphoma refractory ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0855090
Disease: B-cell lymphoma refractory
B-cell lymphoma refractory 		0.010 AlteredExpression disease BEFREE Inhibition of the PI3K isoforms p110α/p110δ or mTOR synergized with ibrutinib to induce cell death in <i>CD79B</i>-mutant PCNSL cells.<b>Significance:</b> Ibrutinib has substantial activity in patients with relapsed or refractory B-cell lymphoma of the CNS. 28619981 2017